RESEARCH PEPTIDE FUNDAMENTALS / MATRIX
Four Peptides, Four Different Evidence Pictures
GHK-Cu, PT-141, retatrutide, and semaglutide side by side — mechanism, evidence base, regulatory status, and the one caution that matters most for each.
The short version
This page lines up GHK-Cu, PT-141, retatrutide, and semaglutide on the dimensions that actually matter when reading research-peptide claims: what receptor or pathway each one acts on, what it has actually been studied for, how deep that evidence goes, how it is administered, whether it is approved anywhere, and the single biggest caution for each. The short version: these four are the research peptides most discussed in clinical settings, but they sit at wildly different points on the evidence spectrum. Semaglutide has the deepest trial record. Retatrutide has the biggest Phase 2 numbers and zero approvals. PT-141 is approved for one narrow use and discussed for many others. GHK-Cu has strong topical data and almost no injectable data. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | GHK-Cu | PT-141 (bremelanotide) | Retatrutide | Semaglutide |
|---|---|---|---|---|
| Mechanism | Copper-binding tripeptide; stimulates fibroblasts and copper-dependent collagen cross-linking | MC4R/MC3R melanocortin receptor agonist (central, brain-acting) | GIP/GLP-1/glucagon triple receptor agonist | GLP-1 receptor agonist |
| Most studied for | Skin collagen, wrinkles, hair growth (topical) | Hypoactive sexual desire disorder in premenopausal women [8] | Obesity, type 2 diabetes, fatty liver disease | Type 2 diabetes, obesity, cardiovascular and kidney outcomes |
| Evidence base | Small human topical trials plus cell/rodent work [1][3][4][5] | Two Phase 3 RCTs (n=1,267) plus a 52-week extension [8][9] | Phase 2 only; Phase 3 (TRIUMPH) ongoing, unpublished [14][15] | Large multi-thousand-participant RCTs across several indications [16][17][18][19][22] |
| Administration studied | Topical (creams/serums); no validated injectable protocol | Once, as-needed subcutaneous injection [10] | Once-weekly subcutaneous injection (Phase 2) [14] | Once-weekly subcutaneous injection; once-daily oral tablet |
| Regulatory status | Legal cosmetic ingredient (topical); no approved injectable/systemic drug product | FDA-approved for HSDD in premenopausal women only; all other use off-label [10] | Investigational; not approved anywhere as of mid-2026 | FDA-approved (diabetes, weight management, CV risk reduction, MASH) |
| Biggest single caution | No human safety basis for injectable/systemic use [1] | Narrow approved population; transient blood-pressure rise; frequent nausea [10] | Unverified gray-market supply; dose-dependent heart-rate increase [14] | GI intolerance drives most discontinuations; boxed thyroid-tumor warning [20] |
Mechanism
The four work through genuinely unrelated systems, which is worth stating directly because "peptide" as a category tells almost nothing about mechanism. GHK-Cu acts locally, on skin cells, largely independent of the bloodstream reaching a receptor in the brain or gut. PT-141 works centrally, on melanocortin receptors in the hypothalamus and limbic system, changing desire signaling rather than blood flow [7]. Retatrutide and semaglutide both work on gut-hormone receptors, but retatrutide adds a third receptor — glucagon — that semaglutide does not touch, which is the entire pharmacological argument for its larger reported weight-loss effect [11][12]. Grouping these four under one label obscures more than it reveals; the mechanism section on each individual page is the one to actually read before drawing conclusions.
Evidence base
This is where the four separate most sharply. Semaglutide's evidence base is the deepest: multiple randomized trials in the thousands-of-participants range, across at least four separate indications, plus years of real-world pharmacovigilance data [16][17][18][19][20][22]. PT-141's evidence is narrower but solid within its lane — two identical Phase 3 trials and a year-long safety extension, all in one specific patient population [8][9]. Retatrutide's entire evidence base is Phase 2: two pivotal trials and one substudy, all published in 2023–2024, with Phase 3 results not yet available [13][14][15]. GHK-Cu's human evidence is the thinnest and most topical-specific: small trials, mostly from a limited set of research groups, with essentially no controlled data on injectable or systemic use at all [1][3][4]. "More research exists" and "the research that exists is strong" are two different claims, and they do not move together across these four.
Regulatory and approval status
Two of these four are approved prescription medicines for specific indications: semaglutide (type 2 diabetes, weight management, cardiovascular risk reduction, and MASH) and PT-141 (HSDD in premenopausal women only) [10][20]. GHK-Cu occupies a different category entirely — it is a legal cosmetic ingredient with no approved drug product, meaning its regulatory status depends entirely on how it is being used (topical skincare versus injection). Retatrutide is not approved anywhere as of mid-2026; it remains investigational, and material sold outside clinical trials as "research-grade" retatrutide has no verified identity or purity, a gap serious enough that the FDA issued dozens of warning letters to vendors in 2025 [11][14]. Approval status is not a formality here — it is the difference between a monitored clinical use and an unverified gray-market product.
Key caution
Each compound has a defining risk worth naming plainly. For GHK-Cu, it is that almost the entire safety and efficacy case is topical — injecting it is a step with no real human data behind it [1]. For PT-141, it is the combination of a narrow approved population and a transient blood-pressure rise that rules it out for people with uncontrolled hypertension or known heart disease [10]. For retatrutide, it is investigational status stacked on top of a documented dose-dependent heart-rate increase, with long-term cardiovascular meaning still unresolved in an ongoing dedicated trial [14]. For semaglutide, it is that gastrointestinal intolerance is the single biggest reason people stop taking it, and a boxed warning for thyroid tumors — based on rodent data, not a confirmed human signal — sits on the label regardless [20]. Reading all four together, the pattern is simple: more mechanistic ambition tends to come with more open safety questions.